Item 8.01. Other Events.
On December 4, 2019, the Board of Directors of Akers Biosciences, Inc. (the
"Company") formed an advisory board (the "Advisory Board") with expertise in the
hemp and minor cannabinoid sectors. The Company will continue its strategic
alternatives review and has identified the hemp and minor cannabinoid sectors as
potential opportunities that could benefit from the Company's core competencies.
The Company is exploring how to leverage its 30 years of operational history in
its medical device business, where its current products have U.S. Food and Drug
Administration (FDA) clearance, its current operations practice Good
Manufacturing Processes (cGMP), its medical device facility is certified under
ISO 13485 - 2016 and the facility carries an Analytical Lab Certification for
Schedules 2, 3, 4 and 5 controlled substances issued by the U.S. Drug
Enforcement Administration (DEA) and the State of New Jersey. The Advisory Board
will assist the Board of Directors in its strategic review including,
potentially, the extraction, testing, purification and formulation of safe
cannabinoids within the hemp industry. The Advisory Board may also explore a
pathway to consumer products with a focus on minor cannabinoids.
Forward- Looking Statements
This report on Form 8-K contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such forward-looking statements are characterized by
future or conditional verbs such as "may," "will," "expect," "intend,"
"anticipate," "believe," "estimate," "continue" and similar words. Such
statements are only predictions and actual events or results may differ
materially from those anticipated in these forward-looking statements. You
should not place undue reliance on any forward-looking statements. The Company
does not assume any obligation to update forward-looking statements as
circumstances change, except as required by securities laws. There can be no
assurance that the Company will be granted the hearing and following the
hearing, the panel will determine to continue to allow the listing of the
Company's common stock on the Nasdaq or that the Company will be able to
evidence compliance with the applicable listing criteria within the period of
time, if any, that may be granted by the panel.
© Edgar Online, source Glimpses